医学
内科学
肿瘤科
淋巴细胞白血病
白血病
细胞疗法
免疫疗法
急性淋巴细胞白血病
化疗
梅德林
临床试验
CD19
癌症
细胞
作者
Lichao Liu,Yongxian Hu,Ruihao Huang,Yuhua Li,Sanfang Tu,Shangjun Chen,Hai Yi,Qiuying Gao,Jian Zhou,Xu Tan,Cheng Zhang,Xiaoqi Wang,Xi Zhang
标识
DOI：10.1097/cm9.0000000000003855
摘要
Both recipient-derived and donor-derived CD19 CAR-T cell therapies are effective treatment options for B-ALL relapsed post-allo-HSCT patients. HID-derived CAR-T cells offer a longer EFS and may be considered the optimal choice.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
22336
Copyright
ale
毗昙
huang
OK
yjh123
arniu2008
勤奋一一
123
aajhajkahna
初景
sagitar
张荣基
GingerF
愉快的真
pluto
Nole
皖公网安备34019202002308
